Scientific papers

  • 2017

  • Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.

    Köhnke T, Wittmann VK, Bücklein VL, Lichtenegger F, Pasalic Z, Hiddemann W, Spiekermann K, Subklewe M.

    Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14901.


  • Recent developments in immunotherapy of acute myeloid leukemia.

    Lichtenegger FS, Krupka C, Haubner S, Köhnke T, Subklewe M.

    J Hematol Oncol. 2017 Jul 25;10(1):142. doi: 10.1186/s13045-017-0505-0. Review.


  • A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia.

    Sandhöfer N, Metzeler KH, Kakadia PM, Pasalic Z, Hiddemann W, Neusser M, Steinlein O, Fiegl M, Subklewe M, Spiekermann K, Bohlander SK, Schneider S, Braess J.

    Genes Chromosomes Cancer. 2017 Apr 18. doi: 10.1002/gcc.22466.


  • Targeting CD157 in AML using a novel, Fc-engineered antibody construct.

    Krupka C, Lichtenegger FS, Köhnke T, Bögeholz J, Bücklein V, Roiss M, Altmann T, Do TU, Dusek R, Wilson K, Bisht A, Terrett J, Aud D, Pombo-Villar E, Rohlff C, Hiddemann W, Subklewe M.

    Oncotarget. 2017 Mar 9. doi: 10.18632/oncotarget.16060.


  • SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.

    Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, Subklewe M, Hopfner KP.

    Oncotarget. 2017 Jan 4. doi: 10.18632/oncotarget.14500.


  • 2016

  • Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.

    Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S.

    J Clin Oncol. 2016 Dec 19:JCO2016693564.


  • Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.

    Bücklein V, Adunka T, Mendler AN, Issels R, Subklewe M, Schmollinger JC, Noessner E.

    Oncoimmunology. 2016 Apr 29;5(7):e1178421. doi: 10.1080/2162402X.2016.1178421.


  • Features of Human CD3+CD20+ T Cells.

    Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, Krane M, Lange R, Pfannes K, Subklewe M, Gürkov R, Bradl M, Hohlfeld R, Kümpfel T, Meinl E, Krumbholz M.

    J Immunol. 2016 Aug 15;197(4):1111-7. doi: 10.4049/jimmunol.1600089.


  • Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

    Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Goerlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K.

    Blood. 2016 Jun 10. pii: blood-2016-01-693879.


  • Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia

    Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weisser T, Steidle S, Schick M, Jacobs L, Slawska J, Mueller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Goetze K, Keller U.

    Haematologica. 2016 May 12. pii: haematol.2016.142976.


  • Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

    Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M.

    Leukemia. 2016 Feb;30(2):484-91. doi: 10.1038/leu.2015.214.


  • 2015

  • RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.

    Lichtenegger FS, Kondla I, Krempasky M, Weber AL, Herold T, Krupka C, Spiekermann K, Schneider S, Büchner T, Berdel WE, Wörmann BJ, Hiddemann W, Subklewe M.

    Cancer Immunol Immunother. 2015 Dec;64(12):1505-15. doi: 10.1007/s00262-015-1755-8.


  • Immunotherapy in Tumors.

    Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.

    Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809.


  • Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.

    Köhnke T, Krupka C, Tischer J, Knösel T, Subklewe M.

    J Hematol Oncol. 2015 Oct 8;8(1):111. doi: 10.1186/s13045-015-0213-6.


  • Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.

    Zugmaier G, Klinger M, Schmidt M, Subklewe M.

    Mol Immunol. 2015 Oct;67(2 Pt A):58-66. doi: 10.1016/j.molimm.2015.02.033. Review.


  • T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.

    Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, Hiddemann W, Subklewe M.

    J Hematol Oncol. 2015 Jul 30;8:93. doi: 10.1186/s13045-015-0189-2.


  • Immunotherapy for Acute Myeloid Leukemia.

    Lichtenegger FS, Krupka C, Köhnke T, Subklewe M.

    Semin Hematol. 2015 Jul;52(3):207-14. doi: 10.1053/j.seminhematol.2015.03.006. Review.


  • Bendamustine and the immune system: a wolf in sheep's clothing?

    Dreyling M, Subklewe M.

    Leuk Lymphoma. 2015 Apr;56(4):837-8. doi: 10.3109/10428194.2015.1024942.


  • Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.

    Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K.

    Leukemia. 2015 Apr;29(4):828-38. doi: 10.1038/leu.2014.305.


  • Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

    Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M.

    Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186.


  • An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.

    Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, André MC, Hiddemann W, Schneider S, Subklewe M, Metzeler KH, Spiekermann K, Jeremias I.

    PLoS One. 2015 Mar 20;10(3):e0120925. doi: 10.1371/journal.pone.0120925.


  • 2014

  • New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.

    Subklewe M, Geiger C, Lichtenegger FS, Javorovic M, Kvalheim G, Schendel DJ, Bigalke I.

    Cancer Immunol Immunother. 2014 Oct;63(10):1093-103. doi: 10.1007/s00262-014-1600-5. Review.


  • Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.

    Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K.

    Haematologica. 2014 Aug;99(8):1317-25. doi: 10.3324/haematol.2014.104133.


  • Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML.

    Lichtenegger FS, Lorenz R, Gellhaus K, Hiddemann W, Beck B, Subklewe M.

    Leuk Res. 2014 Aug;38(8):964-9. doi: 10.1016/j.leukres.2014.05.014.


  • Discovery of Highly Potent p53-MDM2 Antagonists and Structural Basis for Anti-Acute Myeloid Leukemia Activities.

    Huang Y, Wolf S, Beck B, Köhler LM, Khoury K, Popowicz GM, Goda SK, Subklewe M, Twarda A, Holak TA, Dömling A.

    ACS Chem Biol. 2014 Jan 17.


  • CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

    Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.

    Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548.


  • Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.

    Witter K, Reibke R, Subklewe M, Zahn R, Kauke T, Spiekermann K, Spannagl M, Tischer J, Hiddemann W, Dick A.

    Bone Marrow Res. 2014;2014:541345. doi: 10.1155/2014/541345.


  • Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.

    Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, Berdel WE, Büchner T, Woermann BJ, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Polzer H.

    PLoS One. 2014 Mar 7;9(3):e89560. doi: 10.1371/journal.pone.0089560.


  • 2013

  • Structures of the human and Drosophila 80S ribosome.

    Anger AM, Armache JP, Berninghausen O, Habeck M, Subklewe M, Wilson DN, Beckmann R.

    Nature. 2013 May 2;497(7447):80-5. doi: 10.1038/nature12104.


  • Current strategies in immunotherapy for acute myeloid leukemia.

    Lichtenegger FS, Schnorfeil FM, Hiddemann W, Subklewe M.

    Immunotherapy. 2013 Jan;5(1):63-78. doi: 10.2217/imt.12.145. Review.


  • 2012

  • Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.

    Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group.

    Ann Hematol. 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4.


  • Advanced systemic mastocytosis as a mimicker of metastatic clear cell renal cell carcinoma.

    Walz C, Subklewe M, Horny HP, Flaig M, Reiter A, Kirchner T, Sotlar K.

    Leuk Res. 2012 Jun;36(6):799-801. doi: 10.1016/j.leukres.2012.02.031.


  • CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells.

    Lichtenegger FS, Mueller K, Otte B, Beck B, Hiddemann W, Schendel DJ, Subklewe M.

    PLoS One. 2012;7(9):e44266. doi: 10.1371/journal.pone.0044266.


  • 2011

  • Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission.

    Beck B, Dörfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M, Schendel DJ, Subklewe M.

    J Transl Med. 2011 Sep 13;9:151. doi: 10.1186/1479-5876-9-151.


  • 2010

  • Hematology 2010.

    Dreyling M, Subklewe M, Braess J, Spiekermann K.

    Dtsch Med Wochenschr. 2010 Jun;135(25-26):1322-5. doi: 10.1055/s-0030-1255163. Review. German.


  • A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.

    Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS.

    Leuk Lymphoma. 2010 Mar;51(3):447-55. doi: 10.3109/10428190903580402.


  • 2009

  • Hepatosplenic T-cell lymphoma in a patient with Crohn's disease.

    Beigel F, Jürgens M, Tillack C, Subklewe M, Mayr D, Göke B, Brand S, Ochsenkühn T.

    Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):433-6. doi: 10.1038/nrgastro.2009.87. Review.


  • 2008

  • Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.

    Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M.

    Int J Hematol. 2008 Nov;88(4):434-40. doi: 10.1007/s12185-008-0176-2.


  • 2007

  • Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.

    Hammer MH, Brestrich G, Mittenzweig A, Roemhild A, Zwinger S, Subklewe M, Beier C, Kurtz A, Babel N, Volk HD, Reinke P.

    J Immunother. 2007 Nov-Dec;30(8):817-24.


  • Radiologic and pathologic features of a posttransplantation primary central nervous system lymphoma demonstrating Epstein-Barr virus-positive Hodgkin lymphoma.

    Subklewe M, Anagnostopoulos I.

    Clin Lymphoma Myeloma. 2007 Sep;7(8):535-7.


  • Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.

    Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A, Pezzutto A, Riess H, Subklewe M.

    Transpl Immunol. 2007 Apr;17(3):203-10.


  • Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.

    Subklewe M, Sebelin-Wulf K, Beier C, Lietz A, Mathas S, Dörken B, Pezzutto A.

    Hum Immunol. 2007 Mar;68(3):147-55.


  • 2006

  • Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.

    Subklewe M, Marquis R, Choquet S, Leblond V, Garnier JL, Hetzer R, Swinnen LJ, Oertel S, Papp-Vary M, Gonzalez-Barca E, Hepkema BG, Schoenemann C, May J, Pezzutto A, Riess H.

    Transplantation. 2006 Oct 27;82(8):1093-100.


  • Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients.

    Sebelin K, Schulzki A, Kloetzel PM, Dörken B, Pezzutto A, Subklewe M.

    Transplantation. 2006 Sep 27;82(6):779-87.


  • Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.

    Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H, Gärtner B.

    Ann Hematol. 2006 Jul;85(7):478-84.


  • 1994-2005

  • Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.

    Subklewe M, Sebelin K, Block A, Meier A, Roukens A, Paludan C, Fonteneau JF, Steinman RM, Münz C.

    Hum Immunol. 2005 Sep;66(9):938-49.


  • Extramedullary manifestation of a donor-derived acute myeloid leukemia in a liver transplant patient.

    Subklewe M, Nagy M, Schoch C, Jenisch S, Siebert R, Gesk S, Neuhaus P, Dörken B, Schmidt CA.

    Leukemia. 2004 Dec;18(12):2050-3.


  • Dendritic cells for the induction of EBV immunity.

    Subklewe M.

    Recent Results Cancer Res. 2002;159:38-43. Review.


  • Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.

    Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Münz C.

    J Exp Med. 2001 Feb 5;193(3):405-11.


  • Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

    Münz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, Zhang D, O'Donnell M, Steinman RM.

    J Exp Med. 2000 May 15;191(10):1649-60.


  • Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion.

    Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Cox WI, Steinman RM, Bhardwaj N.

    J Immunol. 1999 Dec 15;163(12):6762-8.


  • Presentation of epstein-barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes.

    Subklewe M, Chahroudi A, Bickham K, Larsson M, Kurilla MG, Bhardwaj N, Steinman RM.

    Eur J Immunol. 1999 Dec;29(12):3995-4001.


  • Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus.

    Subklewe M, Chahroudi A, Schmaljohn A, Kurilla MG, Bhardwaj N, Steinman RM.

    Blood. 1999 Aug 15;94(4):1372-81.


  • Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells.

    Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, Pack M, Subklewe M, Sauter B, Sheff D, Albert M, Bhardwaj N, Mellman I, Steinman RM.

    J Exp Med. 1998 Dec 7;188(11):2163-73.


  • A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells.

    Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N.

    Blood. 1997 Nov 1;90(9):3640-6.


  • Expression of surface markers on alveolar macrophages from symptomatic patients with HIV infection as detected by flow cytometry.

    Wasserman K, Subklewe M, Pothoff G, Banik N, Schell-Frederick E.

    Chest. 1994 May;105(5):1324-34.


↑ to the top
  • -